Cargando…

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malignancies. There are many challenges in translating this therapy for T cell disease, includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischer, Lauren C., Spencer, H. Trent, Raikar, Sunil S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936092/ https://www.ncbi.nlm.nih.gov/pubmed/31884955 http://dx.doi.org/10.1186/s13045-019-0801-y

Ejemplares similares

Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors
por: Moot, Robert, et al.
Publicado: (2016)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

TCR-T Immunotherapy: The Challenges and Solutions
por: Liu, Yating, et al.
Publicado: (2022)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

CAR T-cell immunotherapy of B-cell malignancy: the story so far
por: Halim, Leena, et al.
Publicado: (2020)

CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets
por: Maher, John, et al.
Publicado: (2023)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Exhaustion of CAR T cells: potential causes and solutions
por: Kouro, Taku, et al.
Publicado: (2022)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
por: Zoine, Jaquelyn T., et al.
Publicado: (2019)

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
por: Alvanou, Maria, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens
por: Maher, John, et al.
Publicado: (2023)

CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
por: Maggs, Luke, et al.
Publicado: (2021)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

New cell sources for CAR-based immunotherapy
por: Mazinani, Marzieh, et al.
Publicado: (2023)

TOX as a potential target for immunotherapy in lymphocytic malignancies
por: Liang, Chaofeng, et al.
Publicado: (2021)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
por: Su, Yang, et al.
Publicado: (2023)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy
por: Arman, Inbar, et al.
Publicado: (2022)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Recent Advances in CAR-Based Solid Tumor Immunotherapy
por: Shin, Min Hwa, et al.
Publicado: (2023)

CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
por: Narkhede, Mayur, et al.
Publicado: (2021)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies
por: Walti, Carla S, et al.
Publicado: (2020)

Versatile CAR T-cells for cancer immunotherapy
por: Chu, Fuliang, et al.
Publicado: (2018)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n2dd0ispljkegidmov15rqp347